COVID vaccine patents not discussed at G7 health ministers meeting
Reuters
Published May 19, 2022 13:20
BERLIN (Reuters) - The question of COVID-19 vaccine patents was not discussed at a meeting of the health ministers of the Group of Seven (G7) countries in Berlin, German Health Ministers Karl Lauterbach said on Thursday.
"We haven't discussed the release of patents because the question hasn't come up yet, but that can definitely happen," Lauterbach told a joint news conference with German Development Minister Svenja Schulze.
"The problem we currently have is that of middle- and lower-income countries' willingness to use the vaccine," Lauterbach said, adding that there was more vaccine available than people ready to take it.
Germany is against a planned intellectual property waiver for COVID-19 vaccines, saying patents are a crucial way of encouraging companies to continue pushing ahead with new research.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.